Cognition Therapeutics Inc. (CGTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2403 SIDNEY STREET
PITTSBURGH, PA 15203
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29,922,00041,562,00054,721,000
Cash and cash equivalents29,922,00041,562,00054,721,000
Receivables1,281,0003,672,0002,266,000
Prepaid expense3,019,0002,413,0001,994,000
Other current assets   11,000
Total current assets:34,222,00047,647,00058,992,000
Noncurrent Assets
Operating lease, right-of-use asset657,000813,000 
Property, plant and equipment284,000233,000145,000
Other undisclosed noncurrent assets  1,732,000 
Total noncurrent assets:941,0002,778,000145,000
TOTAL ASSETS:35,163,00050,425,00059,137,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,750,0005,310,0005,919,000
Accounts payable3,695,0003,216,0004,168,000
Accrued liabilities4,055,0002,094,0001,751,000
Other liabilities544,000634,0001,945,000
Other undisclosed current liabilities1,875,0001,851,000 
Total current liabilities:10,169,0007,795,0007,864,000
Noncurrent Liabilities
Liabilities, other than long-term debt520,0002,381,000 
Other liabilities  1,686,000 
Operating lease, liability520,000695,000 
Total noncurrent liabilities:520,0002,381,000 
Total liabilities:10,689,00010,176,0007,864,000
Equity
Equity, attributable to parent24,474,00040,249,00051,273,000
Common stock32,00029,00022,000
Additional paid in capital165,826,000155,820,000145,453,000
Accumulated other comprehensive loss (195,000)(199,000)(198,000)
Accumulated deficit(141,189,000)(115,401,000)(94,004,000)
Total equity:24,474,00040,249,00051,273,000
TOTAL LIABILITIES AND EQUITY:35,163,00050,425,00059,137,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Operating expenses(50,724,000)(43,551,000)(28,598,000)
Operating loss:(50,724,000)(43,551,000)(28,598,000)
Nonoperating income
(Other Nonoperating income)
24,936,00022,154,00016,882,000
Interest and debt expense   (895,000)
Loss from continuing operations:(25,788,000)(21,397,000)(12,611,000)
Loss before gain (loss) on sale of properties:(12,611,000)
Net loss:(25,788,000)(21,397,000)(12,611,000)
Other undisclosed net income attributable to parent   895,000
Net loss attributable to parent:(25,788,000)(21,397,000)(11,716,000)
Preferred stock dividends and other adjustments   (4,532,000)
Net loss available to common stockholders, diluted:(25,788,000)(21,397,000)(16,248,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(25,788,000)(21,397,000)(12,611,000)
Other comprehensive income (loss)4,000(1,000)(11,000)
Other undisclosed comprehensive income   
Comprehensive loss:(25,784,000)(21,398,000)(12,622,000)
Other undisclosed comprehensive income, net of tax, attributable to parent  895,000
Comprehensive loss, net of tax, attributable to parent:(25,784,000)(21,398,000)(11,727,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: